BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34920797)

  • 1. [DESCAR-T, a nationwide registry for patient treated by CAR-T Cells in France].
    Broussais F; Bay JO; Boissel N; Baruchel A; Arnulf B; Morschhauser F; Robin M; Guepin GR; Moreau P; Gandemer V; Manier S; Leguay T; Nguyen Quoc S; Schwartzmann A; Houot R; Le Gouill S
    Bull Cancer; 2021 Oct; 108(10S):S143-S154. PubMed ID: 34920797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A standardized medical report template for CAR T-Cell therapy patients: Guidelines of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
    Broussais F; Vasseur A; Karam M; Chaillou D; Pereira M; Yakoub-Agha I; Raus N
    Bull Cancer; 2021 Dec; 108(12S):S82-S86. PubMed ID: 33933288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunomonitoring of patients treated with CAR-T cells for hematological malignancy: Guidelines from the CARTi group and the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
    Rubio MT; Varlet P; Allain V; Ballot C; Cuffel A; Deschamps M; Ferrand C; Foguenne J; Forcade E; Huynh A; Guihot A; Latouche JB; Lemarie C; Martinroche G; Morin F; Nguyen S; Schmit K; Servais S; Simonetta F; Yakoub-Agha I; Caillat Zucman S
    Bull Cancer; 2021 Dec; 108(12S):S53-S64. PubMed ID: 34253335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
    Pegram HJ; Smith EL; Rafiq S; Brentjens RJ
    Immunotherapy; 2015; 7(5):545-61. PubMed ID: 26065479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late Events After CD-19 CAR-T Treatment.
    Hossain NM; Nishimura MI
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):e1-e2. PubMed ID: 31669398
    [No Abstract]   [Full Text] [Related]  

  • 6. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CAR T cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
    Alsuliman T; Drieu La Rochelle L; Campidelli A; Duléry R; Fayard A; Mamez AC; Mear JB; Schneider PO; Trevet A; Vicente C; Yakoub-Agha I
    Bull Cancer; 2021 Dec; 108(12S):S65-S71. PubMed ID: 33678408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [CAR-T CELLS: How does the EBMT registry monitor European activities, identify hurdles and prepare for changes in regulations].
    Chabannon C; Lemaitre J; Peffault de Latour R; Neven B; Bay JO; Robin M; Kuball J; Terwel S; Mohty M; Yakoub-Agha I
    Bull Cancer; 2021 Oct; 108(10S):S155-S161. PubMed ID: 34920798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies.
    Cooper ML; DiPersio JF
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101097. PubMed ID: 31779968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
    Zhang M; Huang H
    Front Immunol; 2020; 11():611710. PubMed ID: 33384696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR T-cells for relapsed B-cell ALL in children and young adults.
    Stirrups R
    Lancet Oncol; 2018 Mar; 19(3):e144. PubMed ID: 29429913
    [No Abstract]   [Full Text] [Related]  

  • 13. The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies.
    Cao JX; Gao WJ; You J; Wu LH; Liu JL; Wang ZX
    Cytotherapy; 2019 Jul; 21(7):769-781. PubMed ID: 31160157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR T-cells for relapsed B-cell ALL in adults.
    Gilbert JA
    Lancet Oncol; 2018 Mar; 19(3):e143. PubMed ID: 29429915
    [No Abstract]   [Full Text] [Related]  

  • 15. [Role of allogeneic hematopoietic cell transplantation after anti-CD19 CAR T-cell treatment: Guidelines from the SFGM-TC].
    Beauvais D; Castilla-Llorente C; Diral E; Sirvent A; Vandewiele A; Baruchel A; Yakoub-Agha I; Yakouben K
    Bull Cancer; 2023 Feb; 110(2S):S108-S115. PubMed ID: 35791974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress.
    Holstein SA; Lunning MA
    Clin Pharmacol Ther; 2020 Jan; 107(1):112-122. PubMed ID: 31622496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes.
    Roselli E; Faramand R; Davila ML
    J Clin Invest; 2021 Jan; 131(2):. PubMed ID: 33463538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [How to perform leukapheresis for procurement of the staring material used for commercial CAR T-cell manufacturing: A consensus from experts convened by the SFGM-TC].
    Carnoy S; Beaumont JL; Kanouni T; Parquet N; Beauvais D; Hequet O; Kanold J; Ballot C; Mialou V; Reppel L; Damaj G; Yakoub-Agha I; Chabannon C
    Bull Cancer; 2021 Mar; 108(3):295-303. PubMed ID: 33610284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR T-cells in acute lymphoblastic leukemia: Current results.
    Dourthe ME; Baruchel A
    Bull Cancer; 2021 Oct; 108(10S):S40-S54. PubMed ID: 34920807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR T-Cell Therapy in Hematological Malignancies.
    Haslauer T; Greil R; Zaborsky N; Geisberger R
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.